2-Imidazoline (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "2-Imidazoline" in English language version.

refsWebsite

Global rank English rank

12doi.org

2^nd place

12nih.gov

4^th place

4semanticscholar.org

11^th place

8^th place

1web.archive.org

1^st place

1harvard.edu

18^th place

17^th place

1springer.com

274^th place

309^th place

1worldcat.org

5^th place

doi.org

Liu H, Du DM (March 2009). "Recent Advances in the Synthesis of 2-Imidazolines and Their Applications in Homogeneous Catalysis". Advanced Synthesis & Catalysis. 351 (4): 489–519. doi:10.1002/adsc.200800797.
Crouch RD (March 2009). "Synthetic routes toward 2-substituted 2-imidazolines". Tetrahedron. 65 (12): 2387–2397. doi:10.1016/j.tet.2008.12.022.
Guinchard X, Vallée Y, Denis JN (May 2007). "Total synthesis of marine sponge bis(indole) alkaloids of the topsentin class". The Journal of Organic Chemistry. 72 (10): 3972–3975. doi:10.1021/jo070286r. PMID 17444688.
Macinnes N, Duty S (December 2004). "Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway". British Journal of Pharmacology. 143 (8): 952–959. doi:10.1038/sj.bjp.0706019. PMC 1575965. PMID 15545290.
Dardonville C, Rozas I (September 2004). "Imidazoline binding sites and their ligands: an overview of the different chemical structures". Medicinal Research Reviews. 24 (5): 639–661. doi:10.1002/med.20007. PMID 15224384. S2CID 31258438.
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. (February 2004). "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2". Science. 303 (5659): 844–848. Bibcode:2004Sci...303..844V. doi:10.1126/science.1092472. PMID 14704432. S2CID 16132757.
Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding Q, Jiang N, et al. (May 2013). "Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development". ACS Medicinal Chemistry Letters. 4 (5): 466–469. doi:10.1021/ml4000657. PMC 4027145. PMID 24900694.
Bazanov DR, Pervushin NV, Savin EV, Tsymliakov MD, Maksutova AI, Sosonyuk SE, et al. (December 2021). "Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors". Medicinal Chemistry Research. 30 (12): 2216–2227. doi:10.1007/s00044-021-02802-w. ISSN 1054-2523. S2CID 241788123.
Bazanov DR, Pervushin NV, Savitskaya VY, Anikina LV, Proskurnina MV, Lozinskaya NA, Kopeina GS (August 2019). "2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation". Bioorganic & Medicinal Chemistry Letters. 29 (16): 2364–2368. doi:10.1016/j.bmcl.2019.06.007. PMID 31196710. S2CID 189815065.
Bazanov DR, Pervushin NV, Savin EV, Tsymliakov MD, Maksutova AI, Savitskaya VY, et al. (April 2022). "Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core". Pharmaceuticals. 15 (4): 444. doi:10.3390/ph15040444. PMC 9027661. PMID 35455441.
Tyagi R, Tyagi VK, Pandey SK (2007). "Imidazoline and its derivatives: an overview". Journal of Oleo Science. 56 (5): 211–222. doi:10.5650/jos.56.211. PMID 17898484.
Ishihara M, Togo H (2006). "An Efficient Preparation of 2-Imidazolines and Imidazoles from Aldehydes with Molecular Iodine and (Diacetoxyiodo)benzene". Synlett (2): 227–230. doi:10.1055/s-2005-923604.

harvard.edu

ui.adsabs.harvard.edu

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. (February 2004). "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2". Science. 303 (5659): 844–848. Bibcode:2004Sci...303..844V. doi:10.1126/science.1092472. PMID 14704432. S2CID 16132757.

nih.gov

pubmed.ncbi.nlm.nih.gov

Guinchard X, Vallée Y, Denis JN (May 2007). "Total synthesis of marine sponge bis(indole) alkaloids of the topsentin class". The Journal of Organic Chemistry. 72 (10): 3972–3975. doi:10.1021/jo070286r. PMID 17444688.
Macinnes N, Duty S (December 2004). "Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway". British Journal of Pharmacology. 143 (8): 952–959. doi:10.1038/sj.bjp.0706019. PMC 1575965. PMID 15545290.
Dardonville C, Rozas I (September 2004). "Imidazoline binding sites and their ligands: an overview of the different chemical structures". Medicinal Research Reviews. 24 (5): 639–661. doi:10.1002/med.20007. PMID 15224384. S2CID 31258438.
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. (February 2004). "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2". Science. 303 (5659): 844–848. Bibcode:2004Sci...303..844V. doi:10.1126/science.1092472. PMID 14704432. S2CID 16132757.
Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding Q, Jiang N, et al. (May 2013). "Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development". ACS Medicinal Chemistry Letters. 4 (5): 466–469. doi:10.1021/ml4000657. PMC 4027145. PMID 24900694.
Bazanov DR, Pervushin NV, Savitskaya VY, Anikina LV, Proskurnina MV, Lozinskaya NA, Kopeina GS (August 2019). "2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation". Bioorganic & Medicinal Chemistry Letters. 29 (16): 2364–2368. doi:10.1016/j.bmcl.2019.06.007. PMID 31196710. S2CID 189815065.
Bazanov DR, Pervushin NV, Savin EV, Tsymliakov MD, Maksutova AI, Savitskaya VY, et al. (April 2022). "Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core". Pharmaceuticals. 15 (4): 444. doi:10.3390/ph15040444. PMC 9027661. PMID 35455441.
Tyagi R, Tyagi VK, Pandey SK (2007). "Imidazoline and its derivatives: an overview". Journal of Oleo Science. 56 (5): 211–222. doi:10.5650/jos.56.211. PMID 17898484.

ncbi.nlm.nih.gov

Macinnes N, Duty S (December 2004). "Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway". British Journal of Pharmacology. 143 (8): 952–959. doi:10.1038/sj.bjp.0706019. PMC 1575965. PMID 15545290.
"Clonidine". Pubmed Health. October 2008. Archived from the original on 28 June 2010.
Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding Q, Jiang N, et al. (May 2013). "Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development". ACS Medicinal Chemistry Letters. 4 (5): 466–469. doi:10.1021/ml4000657. PMC 4027145. PMID 24900694.
Bazanov DR, Pervushin NV, Savin EV, Tsymliakov MD, Maksutova AI, Savitskaya VY, et al. (April 2022). "Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core". Pharmaceuticals. 15 (4): 444. doi:10.3390/ph15040444. PMC 9027661. PMID 35455441.

semanticscholar.org

api.semanticscholar.org

Dardonville C, Rozas I (September 2004). "Imidazoline binding sites and their ligands: an overview of the different chemical structures". Medicinal Research Reviews. 24 (5): 639–661. doi:10.1002/med.20007. PMID 15224384. S2CID 31258438.
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. (February 2004). "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2". Science. 303 (5659): 844–848. Bibcode:2004Sci...303..844V. doi:10.1126/science.1092472. PMID 14704432. S2CID 16132757.
Bazanov DR, Pervushin NV, Savin EV, Tsymliakov MD, Maksutova AI, Sosonyuk SE, et al. (December 2021). "Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors". Medicinal Chemistry Research. 30 (12): 2216–2227. doi:10.1007/s00044-021-02802-w. ISSN 1054-2523. S2CID 241788123.
Bazanov DR, Pervushin NV, Savitskaya VY, Anikina LV, Proskurnina MV, Lozinskaya NA, Kopeina GS (August 2019). "2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation". Bioorganic & Medicinal Chemistry Letters. 29 (16): 2364–2368. doi:10.1016/j.bmcl.2019.06.007. PMID 31196710. S2CID 189815065.

springer.com

link.springer.com

Bazanov DR, Pervushin NV, Savin EV, Tsymliakov MD, Maksutova AI, Sosonyuk SE, et al. (December 2021). "Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors". Medicinal Chemistry Research. 30 (12): 2216–2227. doi:10.1007/s00044-021-02802-w. ISSN 1054-2523. S2CID 241788123.

web.archive.org

"Clonidine". Pubmed Health. October 2008. Archived from the original on 28 June 2010.

worldcat.org

search.worldcat.org

Bazanov DR, Pervushin NV, Savin EV, Tsymliakov MD, Maksutova AI, Sosonyuk SE, et al. (December 2021). "Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors". Medicinal Chemistry Research. 30 (12): 2216–2227. doi:10.1007/s00044-021-02802-w. ISSN 1054-2523. S2CID 241788123.